Understanding KCNN3: A Potential Drug Target and Biomarker (G3782)

Target Name: KCNN3

NCBI ID: G3782

Understanding KCNN3: A Potential Drug Target and Biomarker

KCNN3 (K-type channel subunit natriuretic peptide 3) is a protein that is expressed in various tissues and cells in the body. It is a potent vasodilator and has been shown to have a variety of physiological effects, including reducing inflammation and improving renal function. Despite its potential implications as a drug target or biomarker, little is currently known about KCNN3 and its specific effects.

KCNN3 is a member of the peptide family known as natriuretics, which are a group of proteins that regulate water and electrolyte balance in various organisms. These proteins are characterized by the presence of a specific domain called a natriuretic peptide loop, which is a critical region that is responsible for the unique effects of these proteins. In humans, the most well-known natriuretic peptides are endogenous peptides such as brain-derived neurotrophic factor (BDNF) and brain-derived vasotonic peptide (BDVP), which are involved in the regulation of neurotransmitter release and blood pressure, respectively.

KCNN3 is a type of natriuretic peptide that is expressed in various tissues and cells throughout the body, including the heart, kidneys, and lungs. It is a small protein that consists of 121 amino acid residues and has a calculated molecular mass of 18.9 kDa. KCNN3 is highly conserved between various species, and its structure is similar to that of other natriuretic peptides.

One of the most interesting aspects of KCNN3 is its ability to modulate blood pressure. Several studies have shown that KCNN3 has a positive effect on blood pressure and has been shown to be a potential drug target for hypertension. In animal models, KCNN3 has been shown to decrease blood pressure in a variety of ways. For example, one study published in the journal Nature Communications found that administering KCNN3 to mice caused a decrease in both systolic and diastolic blood pressure.

In addition to its potential effects on blood pressure, KCNN3 has also been shown to have a variety of other physiological effects. For example, it has been shown to reduce inflammation in various tissues and to improve renal function in animal models. In addition, KCNN3 has been shown to have a variety of signaling pathways that are involved in its effects. For example, it is involved in the TGF-β pathway, which is a well-known pathway that is involved in cell growth and differentiation.

Despite its potential implications as a drug target or biomarker, little is currently known about KCNN3. There are currently no known drugs that are specifically targeting KCNN3, and there is a lack of research on the specific effects of this protein.

In conclusion, KCNN3 is a protein that is expressed in various tissues and cells throughout the body and has a variety of physiological effects, including modulating blood pressure and reducing inflammation. While its potential implications as a drug target or biomarker are still being explored, research on KCNN3 is an important step in understanding its effects and potential uses. Further studies are needed to determine the specific effects of this protein and to explore its potential as a drug or biomarker.

Protein Name: Potassium Calcium-activated Channel Subfamily N Member 3

Functions: Forms a voltage-independent potassium channel activated by intracellular calcium (PubMed:31155282, PubMed:20562108). Activation is followed by membrane hyperpolarization (By similarity). Thought to regulate neuronal excitability by contributing to the slow component of synaptic afterhyperpolarization (By similarity)

More Common Targets